Third quarter 2023 revenues increased 23% to US$66.7 million, compared to the third quarter 2022, driven by RUCONEST® revenue and the U.S. commercial launch of Joenja®
Nine month year to date 2023 revenues increased 9% to US$164.1 million, compared to nine month year to date 2022
RUCONEST® revenues increased 11% in the third quarter 2023 to US$60.2 million, compared to the third quarter 2022, and increased 18% compared to the second quarter 2023
RUCONEST® nine month year to date 2023 revenues increased by 2% YoY; on track for low single digit annual revenue growth
Continued strength in U.S. Joenja® (leniolisib) launch during the third quarter 2023; 63 patients on paid therapy and US$6.5 million revenue
Overall cash and marketable securities of US$199.2 million at the end of the third quarter 2023, compared to US$194.1 million at the end of the second quarter 2023

see & read more on
https://www.pharming.com/news/pharming-group-reports-third-quarter-2023-financial-results